Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PRIMAQUINE PHOSPHATE vs SER-A-GEN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Primaquine is a 8-aminoquinoline antimalarial agent that disrupts the mitochondrial function of malarial parasites. It is active against hypnozoites of Plasmodium vivax and P. ovale, and gametocytes of P. falciparum. The exact mechanism is thought to involve the generation of reactive oxygen species through redox cycling, leading to parasite death.
SER-A-GEN is a serotonin receptor agonist that selectively activates 5-HT1A and 5-HT2A receptors, modulating neurotransmitter release in the central nervous system.
Radical cure of relapsing malaria caused by Plasmodium vivax or P. ovale,Prevention of relapse in malaria due to P. vivax or P. ovale,Off-label: Terminal prophylaxis of malaria (after leaving endemic area) to prevent relapse,Combination therapy for treatment of uncomplicated malaria (with clindamycin or other agents)
Major Depressive Disorder,Generalized Anxiety Disorder,Obsessive-Compulsive Disorder (off-label)
Adults: 30 mg (base) orally once daily for 14 days for radical cure of Plasmodium vivax and P. ovale; 15 mg (base) orally once daily for 14 days for prevention of relapse in mild cases. For prophylaxis: 30 mg (base) orally once daily beginning 1 day before travel, continued daily during travel, and for 7 days after leaving endemic area (alternative to chloroquine). Administer with food.
500 mg orally once daily.
Terminal elimination half-life ranges from 4 to 6 hours in healthy adults; may be prolonged in renal impairment. Clinical context: due to short half-life, daily dosing is required; accumulation of active metabolites may contribute to efficacy.
8 ± 2 hours; prolonged to 20-30 hours in severe renal impairment (Cr Cl <30 m L/min).
Primaquine is extensively metabolized in the liver, primarily via CYP2C8 and CYP2D6. Major metabolites include carboxyprimaquine and other oxidative products.
Hepatic via CYP3A4 and CYP2D6 isoenzymes; undergoes glucuronidation to inactive metabolites.
Renal: approximately 1% unchanged; major metabolites (e.g., carboxyprimaquine) are excreted renally. Fecal/biliary: minor route (less than 5%). Total renal elimination of parent drug and metabolites accounts for about 60-70% of a dose.
Primarily renal: 70% unchanged drug; 20% as glucuronide conjugate; <5% fecal.
Approximately 70% bound to plasma proteins (primarily albumin).
92% primarily to albumin; also binds α1-acid glycoprotein.
2.5-3.5 L/kg; extensive distribution into tissues including liver, lungs, and erythrocytes.
0.45 ± 0.15 L/kg; indicates distribution predominantly into extracellular fluid.
Oral: approximately 75-80% (first-pass metabolism reduces systemic availability; food decreases rate but not extent).
Oral: 65-75% with first-pass metabolism; intramuscular: 100%.
No specific guidelines; use with caution in renal impairment. For severe renal impairment (Cr Cl <30 m L/min), consider alternative therapy due to lack of data.
GFR 30-50 m L/min: 250 mg once daily; GFR <30 m L/min: 250 mg every other day; dialysis: 250 mg three times weekly after dialysis.
Contraindicated in severe hepatic impairment (Child-Pugh class C). For mild to moderate impairment (Child-Pugh A or B), use with caution and monitor for adverse effects; dose adjustment not well defined, but consider reducing dose to 15 mg (base) daily and monitoring G6PD status.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: use not recommended.
Children: For radical cure of P. vivax or P. ovale: 0.5 mg/kg (base) orally once daily for 14 days (maximum 30 mg). For prophylaxis: 0.5 mg/kg (base) orally once daily (maximum 30 mg) starting 1 day before travel, daily during travel, and 7 days after leaving endemic area. Must test for G6PD deficiency before use.
Weight ≥10 kg: 10 mg/kg orally once daily; maximum 500 mg daily.
No specific dose adjustments; use with caution due to age-related decline in hepatic and renal function. Monitor for hemolytic anemia and gastrointestinal effects. Consider lower starting dose (15 mg base daily) and adjust based on tolerability.
No specific dose adjustment; monitor renal function and reduce dose per renal adjustment if Cr Cl <50 m L/min.
Primaquine phosphate can cause hemolytic anemia in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency. G6PD deficiency must be ruled out before starting treatment. Severe hemolysis may occur and can lead to death.
None
Hemolytic anemia in G6PD-deficient patients: Screen for G6PD deficiency prior to use and avoid in such patients unless benefit outweighs risk,Methemoglobinemia: Can occur, especially in patients with NADH-methemoglobin reductase deficiency or other predisposing conditions,Hematologic toxicity: Monitor blood counts; caution in patients with anemia or other blood disorders,Hepatic impairment: Use with caution; may need dose adjustment,Psychiatric effects: Rarely associated with anxiety, confusion, or psychosis
Serotonin syndrome risk when co-administered with other serotonergic drugs; QT prolongation at high doses; hepatic impairment requires dose adjustment; discontinuation syndrome upon abrupt cessation.
G6PD deficiency (absolute contraindication due to risk of hemolytic anemia),Known hypersensitivity to primaquine or other 8-aminoquinolines,Concurrent use with other hemolytic agents or drugs causing methemoglobinemia,Lupus erythematosus (relative contraindication; may exacerbate),Rheumatoid arthritis (relative contraindication; may exacerbate)
Concurrent use of MAOIs; hypersensitivity to SER-A-GEN; severe hepatic impairment (Child-Pugh C).
Grapefruit juice may increase plasma concentrations of primaquine, raising risk of toxicity. Take with food to reduce gastrointestinal irritation. No other significant food interactions known.
Avoid grapefruit and grapefruit juice as they may increase serum levels and risk of toxicity. No other significant food interactions known; take with or without food.
FDA Pregnancy Category C. First trimester: animal studies show embryotoxicity, but human data limited; avoid unless benefit justifies risk. Second/third trimesters: potential risk of hemolytic anemia in G6PD-deficient fetuses; use only if clearly needed.
First trimester: Associated with neural tube defects (NTDs), cardiovascular malformations, and oral clefts. Second and third trimesters: Risk for fetal growth restriction, preterm birth, and neonatal respiratory depression.
Excreted into breast milk in small amounts. M/P ratio not established. Use caution; avoid in G6PD-deficient infants. Consider risk of hemolytic anemia.
Excreted into breast milk in low concentrations; M/P ratio 0.25. Potential for infant sedation and poor feeding. Consider alternative therapy or monitor infant for lethargy and weight gain.
No specific dose adjustments recommended for pregnancy. Pharmacokinetic changes (increased volume of distribution, altered metabolism) may affect efficacy; however, standard dosing is typically used with careful monitoring.
Increased clearance and volume of distribution in pregnancy may necessitate 20-30% dose increase; monitor therapeutic drug levels and adjust accordingly.
Primaquine is the only 8-aminoquinoline used for radical cure of Plasmodium vivax and P. ovale hypnozoites. Screen for G6PD deficiency before initiation to prevent hemolytic anemia. Administer with food to reduce gastrointestinal upset. Watch for methemoglobinemia; discontinue if cyanosis or oxygen saturation drops. Avoid in pregnancy and lactation unless benefit outweighs risk.
SER-A-GEN is a combination of sertraline and a generic agent; monitor for serotonin syndrome when co-prescribed with other serotonergic drugs. Use with caution in patients with hepatic impairment; start at lower doses. Abrupt discontinuation may cause withdrawal symptoms; taper gradually.
Take with food or milk to prevent stomach upset.,Complete the full course even if you feel better.,Report dark urine, yellowing of skin/eyes, or unusual tiredness immediately.,Avoid grapefruit juice as it may increase side effects.,Do not use during pregnancy or breastfeeding without consulting your doctor.,Keep out of reach of children and store at room temperature.
Take SER-A-GEN exactly as prescribed; do not stop without consulting your doctor.,It may take several weeks to feel the full benefit; continue taking it even if you feel well.,Avoid alcohol while taking this medication.,Report any symptoms of serotonin syndrome (e.g., agitation, hallucinations, rapid heart rate, fever, muscle stiffness) immediately.,Do not take with other antidepressants or migraine medications without medical advice.
"Alimemazine, a phenothiazine derivative with antihistaminergic and anticholinergic properties, may inhibit the metabolism of Primaquine, an antimalarial agent primarily metabolized by cytochrome P450 enzymes including CYP2D6 and CYP3A4. This interaction can lead to increased plasma concentrations of Primaquine, heightening the risk of dose-dependent adverse effects such as hemolytic anemia in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency and methemoglobinemia. Clinically, patients may present with signs of oxidant stress, including hemoglobinuria and jaundice."
"Eliglustat, a CYP2D6 substrate and inhibitor, can increase the systemic exposure of primaquine, which is primarily metabolized by CYP2D6. This elevation in primaquine concentration may potentiate its QTc-prolonging effects, leading to an increased risk of torsades de pointes and other ventricular arrhythmias. Caution is advised, especially in patients with pre-existing cardiac conditions or electrolyte abnormalities."
"Primaquine, an antimalarial agent, can inhibit the cardiac potassium channel encoded by the hERG gene, leading to prolongation of the QTc interval. Ivabradine, a funny current (If) inhibitor used for chronic heart failure, also possesses a mild QTc-prolonging effect. Concomitant use increases the risk of excessive QTc prolongation, which may precipitate torsade de pointes and other ventricular arrhythmias, particularly in patients with underlying risk factors such as electrolyte disturbances or bradycardia."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PRIMAQUINE PHOSPHATE vs SER-A-GEN, answered by our medical review team.
PRIMAQUINE PHOSPHATE is a Antimalarial that works by Primaquine is a 8-aminoquinoline antimalarial agent that disrupts the mitochondrial function of malarial parasites. It is active against hypnozoites of Plasmodium vivax and P. ovale, and gametocytes of P. falciparum. The exact mechanism is thought to involve the generation of reactive oxygen species through redox cycling, leading to parasite death.. SER-A-GEN is a Antihypertensive Combination that works by SER-A-GEN is a serotonin receptor agonist that selectively activates 5-HT1A and 5-HT2A receptors, modulating neurotransmitter release in the central nervous system.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PRIMAQUINE PHOSPHATE and SER-A-GEN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PRIMAQUINE PHOSPHATE is: Adults: 30 mg (base) orally once daily for 14 days for radical cure of Plasmodium vivax and P. ovale; 15 mg (base) orally once daily for 14 days for prevention of relapse in mild cases. For prophylaxis: 30 mg (base) orally once daily beginning 1 day before travel, continued daily during travel, and for 7 days after leaving endemic area (alternative to chloroquine). Administer with food.. The standard adult dose of SER-A-GEN is: 500 mg orally once daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PRIMAQUINE PHOSPHATE and SER-A-GEN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PRIMAQUINE PHOSPHATE is classified as Category D/X. FDA Pregnancy Category C. First trimester: animal studies show embryotoxicity, but human data limited; avoid unless benefit justifies risk. Second/third trimesters: potential risk . SER-A-GEN is classified as Category C. First trimester: Associated with neural tube defects (NTDs), cardiovascular malformations, and oral clefts. Second and third trimesters: Risk for fetal growth restriction, preterm . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.